<DOC>
	<DOCNO>NCT02498275</DOCNO>
	<brief_summary>This exploratory study characterize ex vivo immune response RO6871765 RO7011785 stimulation peripheral blood mononuclear cell ( PBMCs ) extract healthy volunteer chronic hepatitis B ( CHB ) patient .</brief_summary>
	<brief_title>Effect RO6871765 RO7011785 Immune Response With Stimulation Peripheral Blood Mononuclear Cells ( PBMCs ) Chinese Healthy Volunteers Chronic Hepatitis B Patients</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<criteria>All population : Chinese population Adequate hematological function : platelet count great equal ( &gt; = ) 100*10^9 per liter ( /L ) , hemoglobin ( Hb ) &gt; = 12 grams/deciliter ( g/dL ) ( male ) &gt; = 11 g/dL ( female ) , white blood cell ( WBC ) count &gt; = 4*10^9/L &lt; = 11*10^9/L Healthy volunteer : Absence evidence active chronic disease Negative hepatitis B virus deoxyribonucleic acid ( HBV DNA ) , hepatitis B surface antigen ( HBsAg ) , hepatitis B surface antibody ( HBsAb ) , hepatitis B envelope antigen ( HBeAg ) , hepatitis B envelope antiody ( HBeAb ) hepatitis B core antibody ( HBcAb ) Adequate liver function : transaminase alanine aminotransferase ( ALT ) &lt; = 1.0 time upper limit normal ( ULN ) Treatment na√Øve CHB patient : HBsAgpositive ( &gt; =250 international unit/milliliter [ IU/mL ] ) , compensate liver function , noncirrhotic HBeAgpositive , HBV DNA &gt; = 200,000 IU/ml equivalent copies/mL , ALT &gt; 1.5 time ULN ALT &lt; 8 time ULN HBeAgnegative nucleoside/nucleotide analoguetreated CHB patient : Subjects HBeAgseroconverted nucleoside/nucleotide analogue therapy ( treatment 1 3 year prior enrollment ) HBV DNA &lt; 90 IU/mL detection level acceptable sponsor investigator least precede 6 month ; HBeAg negative HBeAb positive HBsAgpositive ( &gt; =250 IU/mL ) , compensate liver function , noncirrhotic ALT &lt; = 1*ULN Use steroid immune suppressive agent within last 4 week would impact number/functions white blood cell ( WBC ) Any disease clinical laboratory find give reasonable suspicion disease condition ( include , limited , cancer , lupus erythematosus , rheumatoid arthritis , autoimmune disease ) could confound result study Positive Hepatitis A immunoglobulin M ( IgM ) antibody , Hepatitis C antibody ( HCV Ab ) human immunodeficiency virus ( HIV ) screen Significant acute infection , example ; influenza , acute gastrointestinal symptom clinically significant illness within 2 week Previous/concurrent treatment interferonbased therapy CHB</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>